Summary of Turn Therapeutics FY Conference Call (February 25, 2026) Company Overview - **Company Name**: Turn Therapeutics (NasdaqGM:TTRX) - **Industry**: Dermatology, focusing on inflammatory skin diseases, particularly eczema and onychomycosis [4][18] Core Points and Arguments Product Pipeline - **Lead Asset**: GX-03, targeting moderate to severe eczema, currently in mid-phase II clinical trial with 214-220 patients [6][7] - **Upcoming Trials**: Phase III trial for toenail fungus (onychomycosis) planned to start in Q1 2027 [7] - **Interim Assessment**: Expected in Q2 2026, with a focus on clinical efficacy and safety [14][30] Mechanism of Action - **Efficacy**: The formula aims to interrupt the IL-36 inflammatory cascade associated with eczema, showing a 57% reduction in disease severity in preclinical models [11][12] - **Safety Profile**: A 53-patient RAPT trial showed no adverse reactions over 580 applications, indicating a strong safety history [13] Market Positioning - **Market Need**: High unmet need in eczema treatment; current options are primarily steroids and systemic biologics, which have significant side effects [15][16][18] - **First-Line Treatment Goal**: Aim to provide a non-steroidal, localized immunomodulator as a first-line treatment for eczema [16][18] Competitive Landscape - **Current Treatments**: Existing topical treatments like JAK inhibitors and PDE4 inhibitors have limited efficacy and significant side effects [15][17] - **Efficacy Comparison**: GX-03 aims to match or exceed the efficacy of current biologics while being non-systemic [30] Financial and Strategic Position - **Low-Burn Model**: The company operates with a low burn rate by outsourcing and utilizing vendors, allowing for flexibility [22] - **Intellectual Property**: Holds over seven patent families and 17 issued patents covering various aspects of its technology [23] - **Partnership Potential**: Open to partnerships with larger pharmaceutical companies to expedite product delivery to patients [39][40] Additional Important Insights - **Patient Demographics**: Emphasis on treating pediatric populations and localizing treatment to prevent systemic issues [30] - **Future Indications**: Interest in expanding to other inflammatory skin diseases like hidradenitis suppurativa and chronic pruritus [22] - **Expertise and Advisory**: The company has a strong advisory team, including former CDC director Dr. Robert Redfield, to navigate regulatory challenges [24] This summary encapsulates the key points discussed during the conference call, highlighting Turn Therapeutics' strategic focus, product pipeline, market positioning, and future outlook.